Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Reprod Toxicol ; 91: 142-146, 2020 01.
Article in English | MEDLINE | ID: mdl-31698003

ABSTRACT

The aim of this study was to directly test and measure in vivo, if placental transfer of monoclonal antibodies takes place in pregnant Göttingen Minipigs to assess their suitability for reproductive assessment of therapeutic monoclonal antibodies. Simulect®, an approved anti CD25 (anti IL-2 receptor alpha) chimeric monoclonal IgG1 antibody, was used as a model monoclonal antibody. Maternal systemic exposure and potential placental transfer of Simulect® to fetuses were investigated following 4 weekly bolus intravenous administration of 5.0 mg/kg from gestation day (GD) 79 or 80 (e.g GD 79, 86, 93 and 100) and with terminal Caesarean section on GD 108 or GD 109 respectively. Results clearly showed exposure in maternal animals, detectable compound in the amniotic fluid from one out of 9 maternal animals, but no exposure in fetuses confirming absence of placental transfer of the selected model antibody Simulect® in minipigs. The absence of Simulect® in the fetuses further supports that the presence of Simulect® in the amniotic fluid in one maternal animal was likely due to contamination with maternal blood during sampling. The demonstrated absence of fetal exposure clearly indicates that, the minipig is not a suitable species for conduct of reproductive toxicity studies with monoclonal antibodies.


Subject(s)
Basiliximab/pharmacokinetics , Immunosuppressive Agents/pharmacokinetics , Maternal-Fetal Exchange , Amniotic Fluid/chemistry , Animals , Basiliximab/blood , Female , Fetal Blood/chemistry , Immunosuppressive Agents/blood , Pregnancy , Swine , Swine, Miniature
2.
Reprod Toxicol ; 80: 35-43, 2018 09.
Article in English | MEDLINE | ID: mdl-29940329

ABSTRACT

The minipig is accepted from scientific and regulatory perspectives for the safety evaluation of drug candidates on embryo-fetal development. The relative size and the duration of gestation (112-115 days) in the minipig is, however, considered a drawback compared with routine smaller species. We evaluated if study duration and cost could be optimized without impacting scientific validity by performing all terminal procedures around mid-gestation (60 days). At this stage, minipig fetal size is not too dissimilar to full term rabbit and therefore better suited to fetal processing/examination compared with at the end of gestation. Despite encountering higher than anticipated embryo-fetal death, morphological defects clearly associated with a known teratogen, pyrimethamine, were detected. Although the gonads are poorly differentiated macroscopically at mid-term, a histological examination confirmed that external sexing of the fetuses was accurate. Double staining of the bone and cartilage of the mid-term fetal skeleton allowed a more refined examination.


Subject(s)
Embryo, Mammalian/drug effects , Embryonic Development/drug effects , Fetal Development/drug effects , Research Design/trends , Swine, Miniature , Teratology/methods , Animals , Bone Development/drug effects , Female , Pregnancy , Swine , Teratogens/toxicity , Teratology/economics , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...